Skip to main content
. 2020 Feb 19;2(1):vdaa018. doi: 10.1093/noajnl/vdaa018

Fig. 2.

Fig. 2

(A) Bar chart depicting numbers of patients (y-axis) expressing specific tumor mutational burden values (x-axis). (B) Representative immunohistochemical micrographs demonstrating low (ii), intermediate (iii), and high (iv) PD-L1 staining and high (vi) PD-1 staining in PCNSL cases with negative controls for PD-L1 (i) and PD-1 (v), respectively. Bar = 1 mm at 20× magnification. (C) Bar chart demonstrating the frequency of expression of immune checkpoint biomarkers in PCNSLs.